Free equity investment tool of Japanese companies

Credit Rating Analysis

Annual

First quarter

Second quarter

Third quarter

Sponsored Link

Related Company

NIPPON PAINT

HISAMITSU PHARMACEUTICAL

Kuraray

塩野義製薬

ダイセル

Fuso Pharmaceutical Industries

アステラス製薬

Kao

Otsuka Holdings

富士製薬工業

エスケー化研

大正製薬ホールディングス

Shin-Etsu Chemical

Mitsubishi Tanabe Pharma

TSUMURA & CO.

EDIUNET Related Ranking

EDIUNET

EDIUNET Credit Rating

EDIUNET Industry Avg

EDIUNET Prefectures

Yuho! Industry

EDIUNET Rating News

Prev « 2024-04 » Next

Mon	Tue	Wed	Thu	Fri	Sat	Sun
1 -	2 -	3 -	4 -	5 -	6 -	7 -
8 -	9 -	10 -	11 -	12 -	13 -	14 -
15 -	16 -	17 -	18 -	19 -	20 -	21 -
22 -	23 -	24 -	25 -	26 -	27 -	28 -
29 -	30 -

[Update list]

1/28 Retail Trade (CAWACHI:A etc...

1/27 Banks (The Awa Bank:BBB→A)

1/23 Chemicals (Milbon:AA→AAA)

1/21 Glass & Ceramics Products (..

1/21 Machinery (TSUDAKOMA:C)

1/21 Other Services (Netindex.:CC)

1/20 Other Products (Kurogane Kos..

1/20 Wholesale Trade (リーバイ・..

1/20 Other Services (川崎地質:BB→..

1/17 Chemicals (Kawaguchi Chemica..

 RSS

 Company RSS

 Daily RSS

Sponsored Link

Recently Download Chart

NIPPON COKE & ENGINEERING

日本アビオニクス

日本アビオニクス

日本アビオニクス

クラリオン

Credit Rating Analysis: TAISHO PHARMACEUTICAL (Annual )

The details of credit rating (bankruptcy risk) can be checked. A credit rating in nine stages (AAA-C).

【Analysis Menu】 Outline Statement Rating Indicator Download

Sponsored Link

Credit Rating (Bankruptcy Risk): TAISHO PHARMACEUTICAL (Annual ) Consolidated | Non-Consolidated

Date	Credit Rating	Comment	Sales	Current Profit	Net Income
2011-03-31	AAA	Credit is extremely high. The highest rating.	¥ 268 B 3.94%	¥ 54 B 47.46%	¥ 34 B 79.07%

Financial Timeline

Date	2011-03-31  (Annual )	2011-06-30  (First quarter )	2011-09-30  (Second quarter )	2011-12-31  (Third quarter )
Credit Rating	AAA	AA	AA	AA
Total Assets	¥ 618 B	¥ 619 B	¥ 627 B	¥ 454 B
Net Assets	¥ 535 B	¥ 539 B	¥ 544 B	¥ 372 B

Financial Statement Risk Analysis: TAISHO PHARMACEUTICAL (Annual ) (Consolidated )

Special note

Operating cash flow, net sales and net income has increased 3 consecutive terms. The performance is very good.

Net Assets have increased 3consecutive terms. The fiscal base is getting better.

Cash(¥ 133 B) is more than the total liabilities(¥ 83 B). It is a very steady fiscal base!

[Date: 2011-03-31]  Danger : Warning : Caution : Good

Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -792 M) & Financial Cash Flow (¥ -18 B) is a minus, Operating Cash Flow (¥ 46 B) is a plus,

Dividend
Under the situation of Net Income (¥ 34 B) & Operating Cash Flow (¥ 46 B) , Dividend (¥ -7 B) is paid.

[Date: 2010-03-31]  Danger : Warning : Caution : Good

Dividend
Under the situation of Net Income (¥ 19 B) & Operating Cash Flow (¥ 39 B) , Dividend (¥ -7 B) is paid.

Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 7 B) is Sales first term ratio (¥ 2 B) more , there is a possibility that the non-performing asset was increased.

[Date: 2009-03-31]  Danger : Warning : Caution : Good

Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -12 B) & Financial Cash Flow (¥ -29 B) is a minus, Operating Cash Flow (¥ 35 B) is a plus,

Dividend
Under the situation of Net Income (¥ 8 B) & Operating Cash Flow (¥ 35 B) , Dividend (¥ -7 B) is paid.

Credit Rating (Bankruptcy Risk): TAISHO PHARMACEUTICAL (Annual ) Consolidated | Non-Consolidated

Date	Credit Rating	Comment	Sales	Current Profit	Net Income
2011-03-31	AA	Credit is very high, slightly affected by biz environs.	¥ 197 B 1.04%	¥ 44 B 31.09%	¥ 29 B 36.64%

Financial Timeline

Date	-  (First quarter )	-  (Second quarter )	-  (Third quarter )	2011-03-31  (Annual )
Credit Rating	-	-	-	AA
Total Assets	-	-	-	¥ 596 B
Net Assets	-	-	-	¥ 540 B

Financial Statement Risk Analysis: TAISHO PHARMACEUTICAL (Annual ) (Non-Consolidated )

Special note

Net income has increased 3 consecutive terms. The performance is good.

Net Assets have increased 3consecutive terms. The fiscal base is getting better.

Cash(¥ 96 B) is more than the total liabilities(¥ 56 B). It is a very steady fiscal base!

[Date: 2011-03-31]  Danger : Warning : Caution : Good

Management Risk (*Gross Income is decrease )
Gross Income (¥ 65 B) is first term Gross Income (¥ 67 B) less , there is a possibility that the management situation has stagnated and deteriorated

Dividend
Under the situation of Net Income (¥ 29 B) & Operating Cash Flow (-) , Dividend (¥ -7 B) is paid.

[Date: 2010-03-31]  Danger : Warning : Caution : Good

Management Risk (*Sales is decrease )
Sales (¥ 195 B) is first term Sales (¥ 198 B) less , there is a possibility that the management situation has stagnated and deteriorated

Management Risk (*Gross Income is decrease )
Gross Income (¥ 67 B) is first term Gross Income (¥ 67 B) less , there is a possibility that the management situation has stagnated and deteriorated

Dividend
Under the situation of Net Income (¥ 21 B) & Operating Cash Flow (-) , Dividend (¥ -7 B) is paid.

Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 7 B) is Sales first term ratio (¥ -3 B) more , there is a possibility that the non-performing asset was increased.

[Date: 2009-03-31]  Danger : Warning : Caution : Good

Dividend
Under the situation of Net Income (¥ 11 B) & Operating Cash Flow (-) , Dividend (¥ -7 B) is paid.

Related Information: TAISHO PHARMACEUTICAL (Annual )

Statement Type

Annual : TAISHO PHARMACEUTICAL

First quarter : TAISHO PHARMACEUTICAL

Second quarter : TAISHO PHARMACEUTICAL

Third quarter : TAISHO PHARMACEUTICAL

Analysis Menu

Outline : TAISHO PHARMACEUTICAL

Statement : TAISHO PHARMACEUTICAL

Rating : TAISHO PHARMACEUTICAL

Indicator : TAISHO PHARMACEUTICAL

Download : TAISHO PHARMACEUTICAL

Industry Comparison Ranking

Chemicals - EDIUNET Industry Rankings

Chemicals - EDIUNET Credit Rating

Chemicals - EDIUNET Industry Avg

Comparison with a neighboring company

Tokyo - EDIUNET Prefectures

Tokyo豊島区 - EDIUNET Prefectures

Related company's newest statement

Date	Company	Credit Rating	Date
1/23	Milbon	AA→AAA	2013-12-20
1/17	Kawaguchi Chemical Indu..	BBB→BB	2013-11-30
1/17	SANKEI CHEMICAL	A	2013-11-30
1/15	HOKKO CHEMICAL INDUSTRY	BB→B	2013-11-30
1/15	Daito Pharmaceutical Co .	AA	2013-11-30 (Q2)
1/15	KAWAKAMI PAINT MFG.	B→BB	2013-11-30
1/15	旭化学工業	AA	2013-11-30 (Q1)
1/10	OSAKA ORGANIC CHEMICAL ..	BB→BBB	2013-11-30
1/10	HISAMITSU PHARMACEUTICAL	A	2013-11-30 (Q3)
1/10	AMS Life Science	BBB→BB	2013-11-30 (Q1)

EDIUNET Investment News (Chemicals)

1/23 Chemicals (Milbon:AA→AAA)

1/17 Chemicals (Kawaguchi Chemica..

1/15 Chemicals (HOKKO CHEMICAL IN..

1/10 Chemicals (OSAKA ORGANIC CHE..

1/9 Chemicals (SANKO GOSEI:A)

12/27 Chemicals (Niitaka:A)

12/18 Chemicals (KUMIAI CHEMICAL I..

12/12 Chemicals (IHARA CHEMICAL IN..

12/11 Chemicals (Konoshima Chemica..

12/10 Chemicals (NATOCO:AA)

Company Information

Ticker	Market	Industry	Month	report	Rating
TAISHO PHARMACEUTICAL	4535	TSE 1st	Chemicals	3	Annual	AAA

Related Company

Kuraray (Sales ¥ 369 B)

Fuso Pharmaceutical Industries (Sales ¥ 48 B)

TSUMURA & CO. (Sales ¥ 105 B)

関西ペイント (Sales ¥ 294 B)

Mitsubishi Tanabe Pharma (Sales ¥ 419 B)

NIHON NOHYAKU (Sales ¥ 47 B)

Kao (Sales ¥ 1.2 T)

Otsuka Holdings (Sales ¥ 1.2 T)

中外製薬 (Sales ¥ 391 B)

キョーリン製薬ホールディングス (Sales ¥ 107 B)

アステラス製薬 (Sales ¥ 1.0 T)

HISAMITSU PHARMACEUTICAL (Sales ¥ 142 B)

富士製薬工業 (Sales ¥ 25 B)

関連する株式投資情報

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .